BILLERICA, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) — Conformis, Inc. (NASDAQ:CFMS) today received a Nov. 25 letter from the Listing Qualifications Division of the NASDAQ Stock Market (“NASDAQ”) announced that , Conformis to Nasdaq Listing Rule 5550 based on the closing price of Conformis common stock on each trading day from November 10, 2022 through November 23, 2022 of at least $1.00 per his share. notified Conformis that it has regained compliance with (a)(2) and the Insufficient Minimum Bid Issues previously disclosed by Conformis are now closed.
As previously reported, Conformis will be listed by NASDAQ on December 31, 2021 as the company’s common stock has posted a minimum bid of $1.00 for the past 30 consecutive days, as required by the listing rules of the Nasdaq stock market. was notified that it could not be maintained. To regain compliance, Conformis had to keep the minimum bid above $1.00 for at least 10 consecutive days. This requirement was met on November 23, 2022. This is his 10th consecutive trading day that the closing price of our common stock exceeded his $1.00.
Founded in 2004, Conformis is a medical technology company focused on advancing care for orthopedic patients and creating a world free of joint pain. Its product portfolio is designed to maximize choice for surgeons and patients by offering fully personalized solutions through Image-to-Implant.® A data-driven, standardized solution that combines the Platinum Services℠ program and the many benefits of personalization with the convenience and flexibility of off-the-shelf systems. Conformis’ sterile, just-in-time Surgery-in-a-Box™ delivery system is available for all implants and personalized disposables. Conformis owns or exclusively licenses issued patents and pending patent applications covering individualized implants and patient-specific appliances for all major joints. For more information, please visit www.conformis.com. Sign up at ir.conformis.com to receive future press releases by email alerts.
Source: Conformis Co., Ltd.